CMPS
COMPASS Pathways plc NASDAQ Listed Sep 18, 2020$9.39
After hrs
$9.97
+0.63%
Mkt Cap $902.2M
52w Low $2.25
89.7% of range
52w High $10.21
50d MA $6.93
200d MA $6.13
P/E (TTM)
-2.9x
EV/EBITDA
-2.9x
P/B
—
Debt/Equity
-0.4x
ROE
544.7%
P/FCF
-4.1x
RSI (14)
—
ATR (14)
—
Beta
2.02
50d MA
$6.93
200d MA
$6.13
Avg Volume
4.2M
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
33 Broadwick Street · London, X0 W1F 0DQ · GB
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 24, 2026 | AMC | -0.41 | -0.59 | -43.9% | 5.22 | +1.7% | +7.7% | +8.0% | +2.9% | +0.4% | +5.9% | — |
| Nov 4, 2025 | AMC | -0.40 | -0.38 | +5.0% | 6.63 | -1.4% | -17.2% | -15.7% | -17.8% | -13.4% | -14.0% | — |
| Jul 31, 2025 | AMC | -0.37 | -0.38 | -2.7% | 4.35 | -1.8% | -0.2% | +5.7% | +3.0% | +0.2% | -0.9% | — |
| May 8, 2025 | AMC | -0.47 | -0.44 | +6.4% | 3.76 | -1.6% | +0.8% | +4.0% | +3.7% | +2.7% | +5.1% | — |
| Feb 27, 2025 | AMC | -0.62 | -0.63 | -1.6% | 3.92 | -0.5% | +0.3% | -6.4% | -1.8% | +3.1% | +2.6% | — |
| Oct 31, 2024 | AMC | -0.60 | -0.56 | +6.7% | 4.76 | -0.2% | -0.2% | -1.7% | -5.0% | -0.6% | +11.3% | — |
| Aug 1, 2024 | AMC | -0.53 | -0.56 | -5.7% | 6.88 | -3.2% | +2.3% | +0.0% | +2.0% | -0.7% | +1.7% | — |
| May 8, 2024 | AMC | -0.52 | -0.55 | -5.8% | 8.50 | +0.7% | +0.5% | -7.5% | -4.5% | -3.9% | -2.6% | — |
| Feb 29, 2024 | AMC | -0.37 | -0.53 | -43.2% | 10.27 | -0.6% | +11.8% | +12.0% | +5.8% | +6.2% | +9.8% | — |
| Nov 2, 2023 | AMC | -0.50 | -0.67 | -34.0% | 5.95 | +1.0% | +7.7% | +4.0% | +1.7% | -6.4% | -9.2% | — |
| Aug 3, 2023 | AMC | -0.69 | -0.62 | +10.1% | 8.98 | +1.8% | -5.0% | -12.4% | -9.1% | -9.5% | -8.8% | — |
| May 11, 2023 | AMC | -0.73 | -0.57 | +21.9% | 8.52 | -0.1% | -3.3% | +0.2% | -1.5% | -0.2% | -1.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 4 | Jefferies | Initiates | Buy | $18 | $9.01 | $9.17 | +1.8% | +5.7% | +3.4% | +8.3% | +4.2% | — |
| Apr 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.89 | $8.75 | -1.6% | -5.1% | -5.7% | +1.9% | +1.3% | +7.1% |
| Apr 24 | B. Riley Securities | Initiates | Buy | $17 | $9.15 | $9.72 | +6.2% | +4.7% | -2.8% | -7.8% | -8.4% | -1.0% |
| Apr 20 | BTIG | Maintains | Buy → Buy | — | $6.66 | $8.65 | +29.9% | +42.0% | +38.9% | +31.4% | +37.4% | +43.8% |
| Mar 26 | Canaccord Genuity | Maintains | Buy → Buy | — | $5.62 | $5.50 | -2.1% | +0.4% | -4.4% | -6.8% | -1.6% | +0.0% |
| Mar 25 | Morgan Stanley | Maintains | Overweight → Overweight | — | $5.22 | $5.31 | +1.7% | +7.7% | +8.0% | +2.9% | +0.4% | +5.9% |
| Mar 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.90 | $6.73 | -2.5% | +1.7% | +0.7% | +2.2% | -1.7% | -4.6% |
| Feb 18 | RBC Capital | Maintains | Outperform → Outperform | — | $7.63 | $8.26 | +8.3% | +10.7% | +8.3% | +5.5% | +2.9% | +4.7% |
| Feb 18 | Morgan Stanley | Maintains | Overweight → Overweight | — | $7.63 | $8.26 | +8.3% | +10.7% | +8.3% | +5.5% | +2.9% | +4.7% |
| Feb 18 | Canaccord Genuity | Maintains | Buy → Buy | — | $7.63 | $8.26 | +8.3% | +10.7% | +8.3% | +5.5% | +2.9% | +4.7% |
| Jan 23 | RBC Capital | Maintains | Outperform → Outperform | — | $7.13 | $7.26 | +1.8% | +0.6% | -3.2% | -2.0% | -5.9% | -4.8% |
| Nov 5 | Morgan Stanley | Maintains | Overweight → Overweight | — | $6.63 | $6.54 | -1.4% | -17.2% | -15.7% | -17.8% | -13.4% | -14.0% |
| Oct 13 | BTIG | Maintains | Buy → Buy | — | $6.22 | $6.26 | +0.6% | +1.1% | +10.0% | +9.8% | +3.1% | +4.8% |
| Aug 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.34 | $4.36 | +0.5% | +6.0% | +3.2% | +0.5% | -0.7% | +1.2% |
| Aug 1 | Canaccord Genuity | Maintains | Buy → Buy | — | $4.35 | $4.27 | -1.8% | -0.2% | +5.7% | +3.0% | +0.2% | -0.9% |
| Jul 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.71 | $3.71 | +0.0% | -4.0% | +5.9% | +4.6% | +15.9% | +20.2% |
| Jul 15 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $3.71 | $3.71 | +0.0% | -4.0% | +5.9% | +4.6% | +15.9% | +20.2% |
| Jun 23 | Evercore ISI | Downgrade | Outperform → In Line | — | $4.63 | $3.08 | -33.5% | -49.2% | -45.4% | -40.4% | -42.5% | -40.2% |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.79 | $4.00 | +5.5% | +3.2% | +2.9% | +1.8% | +4.2% | +5.0% |
| Mar 28 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.09 | $3.06 | -1.0% | -4.9% | -7.4% | -9.7% | +0.0% | -8.4% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.67 | $3.60 | -1.9% | +4.9% | +10.1% | +9.5% | +1.9% | -3.5% |
| Feb 28 | Canaccord Genuity | Maintains | Buy → Buy | — | $3.92 | $3.90 | -0.5% | +0.3% | -6.4% | -1.8% | +3.1% | +2.6% |
| Feb 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.25 | $4.34 | +2.1% | +4.0% | +7.5% | +4.2% | +5.9% | +6.8% |
| Jan 15 | RBC Capital | Maintains | Outperform → Outperform | — | $3.36 | $3.40 | +1.2% | +2.7% | +1.5% | +3.9% | +8.3% | +11.0% |
| Nov 1 | Maxim Group | Maintains | Buy → Buy | — | $4.76 | $4.75 | -0.2% | -0.2% | -1.7% | -5.0% | -0.6% | +11.3% |
| Nov 1 | RBC Capital | Maintains | Outperform → Outperform | — | $4.76 | $4.75 | -0.2% | -0.2% | -1.7% | -5.0% | -0.6% | +11.3% |
| Nov 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.76 | $4.75 | -0.2% | -0.2% | -1.7% | -5.0% | -0.6% | +11.3% |
| Sep 10 | RBC Capital | Maintains | Outperform → Outperform | — | $6.75 | $6.74 | -0.1% | +0.9% | +1.5% | +0.4% | +7.4% | +6.7% |
| Aug 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.95 | $7.18 | +3.3% | +3.5% | +15.1% | +15.1% | +13.7% | +9.9% |
| Aug 2 | Canaccord Genuity | Maintains | Buy → Buy | — | $6.88 | $6.66 | -3.2% | +2.3% | +0.0% | +2.0% | -0.7% | +1.7% |
| Jul 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.61 | $7.65 | +0.5% | +0.3% | -9.6% | -7.5% | -9.6% | -7.8% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.86 | $8.04 | +2.3% | +3.3% | +3.9% | +5.3% | +1.7% | -0.3% |
| Mar 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.27 | $10.21 | -0.6% | +11.8% | +12.0% | +5.8% | +6.2% | +9.8% |
| Aug 22 | Canaccord Genuity | Maintains | Buy → Buy | — | $9.16 | $9.15 | -0.2% | +2.9% | +0.1% | -3.4% | -2.1% | -0.6% |
| Aug 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $9.16 | $9.15 | -0.2% | +2.9% | +0.1% | -3.4% | -2.1% | -0.6% |
| Aug 17 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $9.05 | $8.95 | -1.1% | -7.2% | -9.0% | +1.3% | +4.2% | +1.3% |
| Jul 13 | EF Hutton | Maintains | Buy → Buy | — | $9.06 | $9.07 | +0.1% | +5.2% | +0.3% | +0.8% | +7.3% | +0.3% |
| Jul 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.90 | $9.06 | +1.8% | +4.9% | +11.0% | +19.8% | +13.0% | +1.8% |
| Jun 21 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $8.30 | $8.26 | -0.5% | +0.5% | -3.7% | -5.3% | -8.7% | -5.3% |
| Jun 20 | EF Hutton | Maintains | Buy → Buy | — | $7.69 | $8.07 | +4.9% | +7.9% | +8.5% | +3.9% | +2.2% | -1.4% |
| Jun 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.48 | $7.48 | +0.0% | +9.8% | +10.4% | +7.8% | +4.8% | +7.4% |
| May 30 | EF Hutton | Maintains | Buy → Buy | — | $7.65 | $7.65 | +0.0% | -2.5% | -4.1% | -0.8% | +3.0% | -2.2% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.24 | $8.30 | +0.7% | +3.6% | +1.8% | +3.2% | +2.2% | -2.2% |
| May 11 | EF Hutton | Maintains | Buy → Buy | — | $8.59 | $8.68 | +1.0% | -0.8% | -4.1% | -0.6% | -2.3% | -1.0% |
| Apr 12 | EF Hutton | Maintains | Buy → Buy | — | $10.34 | $10.61 | +2.6% | -2.7% | -3.8% | -3.9% | -2.1% | -4.1% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.97 | $8.00 | +0.4% | -2.8% | +1.5% | +5.8% | +3.1% | +8.9% |
| Mar 1 | Citigroup | Maintains | Buy → Buy | — | $8.25 | $8.32 | +0.8% | -1.5% | +3.6% | +2.9% | -0.4% | -2.1% |
| Feb 28 | EF Hutton | Maintains | Buy → Buy | — | $8.42 | $8.21 | -2.5% | -2.0% | -3.4% | +1.5% | +0.8% | -2.4% |
| Dec 16 | EF Hutton | Maintains | Buy → Buy | — | $9.75 | $10.13 | +3.9% | +0.9% | -4.7% | -5.6% | -6.6% | -8.4% |
| Nov 1 | Loop Capital | Maintains | Buy → Buy | — | $10.54 | $11.24 | +6.6% | +1.0% | -7.0% | -2.6% | -5.1% | -11.2% |
No insider trades available.
8-K · 7.01
! Medium
COMPASS Pathways Plc American Depository Shares -- 8-K 7.01: Regulation FD Disclosure
COMPASS Pathways priced a public offering on February 18, 2026, though specific terms remain unavailable in this filing disclosure.
Feb 19
8-K · 8.01
!! High
COMPASS Pathways Plc American Depository Shares -- 8-K 8.01: Material Event / Announcement
COMPASS Pathways achieved the primary endpoint in its Phase 3 COMP006 trial for COMP360 psilocybin treating treatment-resistant depression, meeting efficacy criteria for potential regulatory approval.
Feb 17
Data updated apr 26, 2026 10:12am
· Source: massive.com